News

The results of the Phase 3 trial showed that the drug was well-tolerated and showed reduction in postsurgical pain over an extended period of time compared with placebo.

Heparin is used to prevent clot formation in central venous catheters and is also used as an anticoagulant (blood thinning) therapy. Heparin is availble in five new vial

Acino will be manufacturing the product at its site in Miesbach, Germany, and will supply the product from there. Acino Group CEO Peter Burema said the alliance between

The results of the trial suggested that once-daily LCP-Tacro is non-inferior in efficacy compared to twice-daily standard tacrolimus tablets (Prograf). The Phase 3 trial was a randomized, multicenter,

The study will evaluate 40 patients with inecalcitol comparing 20 patients with placebo. In the trial, inecalcitol will be administered orally at four milligrams per day for 16

The funding has been awarded by its existing investors along with Forbion Capital Partners, Credit Agricole Private Equity and Vesalius BioCapital. The company has progressed its lead candidate,

NOX-H94 is a Spiegelmer that targets peptide hormone hepcidin, the key regulator of iron metabolism. The trial aims to investigate the tolerability and safety of NOX-H94 with an

The results of the trial demonstrated that Resminostat monotherapy showed substantial anti-tumour activity, including complete and partial tumour responses. Furthermore, the study demonstrated that the drug was safe

The acquisition allows IntrinsiQ to become a part of ION Solutions, a unit of AmerisourceBergen Specialty Group. The combination of IntrinsiQ’s software applications and ION Solutions’ oncology technology